These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 33821824)

  • 1. Weight gain and aging in people with HIV.
    Taramasso L; Stapleton JT; Siedner MJ
    AIDS; 2021 May; 35(6):987-989. PubMed ID: 33821824
    [No Abstract]   [Full Text] [Related]  

  • 2. Do Integrase Inhibitors Cause Weight Gain?
    Wood BR
    Clin Infect Dis; 2020 Mar; 70(7):1275-1277. PubMed ID: 31100105
    [No Abstract]   [Full Text] [Related]  

  • 3. No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir.
    Ciccullo A; Dusina A; Lassandro AP; Borghetti A; Baldin G; Di Giambenedetto S
    AIDS; 2020 May; 34(6):956-957. PubMed ID: 32271256
    [No Abstract]   [Full Text] [Related]  

  • 4. Excessive Weight Gain Associated With Dolutegravir Initiation in a 10-Year-Old Female With Perinatally Acquired Human Immunodeficiency Virus: A Case Report and Review of the Literature.
    Li J; Yusuf EH; Agwu AL
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):373-375. PubMed ID: 32448908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
    Yeoh DK; Campbell AJ; Bowen AC
    Pediatr Infect Dis J; 2021 May; 40(5):e215-e216. PubMed ID: 33847305
    [No Abstract]   [Full Text] [Related]  

  • 6. Weight gain in people living with HIV switched to dual therapy: changes in body fat mass.
    Vizcarra P; Vivancos MJ; Pérez-Elías MJ; Moreno A; Casado JL
    AIDS; 2020 Jan; 34(1):155-157. PubMed ID: 31714355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highlights of AIDS 2020.
    Harris P
    Lancet HIV; 2020 Aug; 7(8):e532. PubMed ID: 32763216
    [No Abstract]   [Full Text] [Related]  

  • 8. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
    Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
    Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weighing considerations with newer antiretrovirals.
    Venter WDF; Hill A
    Lancet HIV; 2020 Jun; 7(6):e374-e375. PubMed ID: 32504568
    [No Abstract]   [Full Text] [Related]  

  • 10. Déjà vu all over again.
    Saag MS; Dumond JB
    AIDS; 2019 Nov; 33(13):2097-2098. PubMed ID: 31577573
    [No Abstract]   [Full Text] [Related]  

  • 11. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
    Taiwo BO; Quiñones-Mateu ME; Smith K; Zheng L; Gulick R; Nyaku AN; Sax PE; Ha B; Kumwenda J; Olefsky M; Godfrey C; Wallis C
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):254-255. PubMed ID: 31914799
    [No Abstract]   [Full Text] [Related]  

  • 12. Bictegravir and dolutegravir: head to head at 96 weeks.
    Barber TJ
    Lancet HIV; 2019 Jun; 6(6):e342-e343. PubMed ID: 31068271
    [No Abstract]   [Full Text] [Related]  

  • 13. Dolutegravir monotherapy as maintenance ART bites the dust.
    Trevillyan JM; Hoy JF
    Lancet HIV; 2017 Dec; 4(12):e531-e532. PubMed ID: 29107563
    [No Abstract]   [Full Text] [Related]  

  • 14. Dolutegravir-induced hyperglycaemia in a patient living with HIV.
    McLaughlin M; Walsh S; Galvin S
    J Antimicrob Chemother; 2018 Jan; 73(1):258-260. PubMed ID: 29077869
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
    Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
    S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
    [No Abstract]   [Full Text] [Related]  

  • 16. Moving forward with dolutegravir in children weighing less than 20 kg.
    Rabie H; Lishman J; Frigati LJ
    Lancet HIV; 2022 May; 9(5):e301-e302. PubMed ID: 35489373
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
    Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
    [No Abstract]   [Full Text] [Related]  

  • 18. "It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda.
    Alhassan Y; Twimukye A; Malaba T; Myer L; Waitt C; Lamorde M; Colbers A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Womens Health; 2022 Jun; 22(1):246. PubMed ID: 35729541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza
    Ciccullo A; Baldin G; Borghi V; Lassandro AP; Farinacci D; Guaraldi G; Mussini C; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2021 May; 37(5):333-334. PubMed ID: 33587009
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing the risk of dolutegravir for women of childbearing potential.
    Schomaker M; Davies MA; Cornell M; Ford N
    Lancet Glob Health; 2018 Sep; 6(9):e958-e959. PubMed ID: 30049617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.